查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602691

阿维莫泮市场：按治疗应用、最终用户划分 - 全球预测 2025-2030

Alvimopan Market by Therapeutic Application (Opioid-Induced Constipation, Postoperative Ileus Prevention), End-User (Hospitals, Surgical Centers) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年阿尔维磨盘市值为62亿美元，预计2024年将达65.1亿美元，复合年增长率为5.23%，到2030年将达到88.7亿美元。

阿维莫泮是一种週边μ阿片受体拮抗剂，主要用于透过减轻阿片类药物引起的胃肠道副作用来促进肠切除手术后胃肠道恢復。阿维莫泮的需求源于其在提高术后復健率、缩短住院时间和降低医疗费用方面的重要作用，特别是考虑到我正在关注的全球外科手术数量不断增加。在医疗保健领域，它主要用作医院和手术中心的术后治疗。 Alvimopan 的最终用途范围也扩展到製药领域，重点是加强术后护理和病患管理通讯协定。医疗保健系统对微创手术和快速復健通讯协定的日益重视是该市场的关键成长要素。探索将适应症和范围扩展到胃肠道恢復以外的药物联合治疗存在潜在的商机。与医疗机构的策略伙伴关係可以提高您的市场渗透率和覆盖范围。然而，监管挑战、高成本和严格的剂量通讯协定等限制构成了主要障碍。由于相关严格指导方针导致的潜在心血管风险和抗药性也可能阻碍市场扩张。其目的是透过先进的药物输送系统（例如基于奈米颗粒的技术）来提高阿维莫泮的生物有效性和疗效，并透过利用人工智慧主导的药物设计策略来优化治疗效果，存在创新机会。研究可以集中在开发更广泛的μ阿片受体拮抗剂，以保留阿维莫泮的益处，同时降低风险。阿维莫泮的市场是利基且高度专业化的，有强有力的临床证据支持其功效，但必须适应复杂的监管环境并证明其安全性才能维持成长。了解市场动态并根据您的需求整合行销策略可以让您在这个不断发展的领域中获得竞争优势。

主要市场统计
基准年[2023] 62亿美元
预测年份 [2024] 65.1亿美元
预测年份 [2030] 88.7亿美元
复合年增长率（%） 5.23%

市场动态：揭示快速发展的 Alvimopan 市场的关键市场洞察

Alvi Mopan 市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 手术介入的增加，包括腹部手术
    • 提高对阿片类药物引起的併发症的认识和管理策略
    • 改善世界各地的医疗保健设施
  • 市场限制因素
    • 法规严格、核准流程长
  • 市场机会
    • 探索阿维莫泮治疗应用的研发计划
    • 增加对公共和私人医疗基础设施的投资
  • 市场挑战
    • 阿维莫泮副作用的风险

波特的五力：驾驭阿维莫泮市场的策略工具

波特的五力框架是了解 Alvimopan 市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 Alvi Mopan 市场的外部影响

外部宏观环境因素在塑造阿维莫泮市场表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解 Alvi Mopan 市场的竞争状况

对 Alvimopan 市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵 Alvimopan 市场供应商绩效评估

FPNV定位矩阵是评估Alvimopan市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製 Alvi Mopan 市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对阿维莫泮市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 手术介入的增加，包括腹部手术
      • 提高对阿片类药物引起的併发症的认识和管理策略
      • 改善世界各地的医疗保健设施
    • 抑制因素
      • 法规严格、核准流程长
    • 机会
      • 探索阿维莫泮治疗应用的研发倡议
      • 增加对公共和私人医疗基础设施的投资
    • 任务
      • 与阿维莫泮相关的副作用风险
  • 市场区隔分析
    • 治疗应用：缓解阿片类药物引起的便秘的多种应用
    • 最终使用者：阿维莫泮在手术中心越来越受欢迎，用于治疗术后肠阻塞
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 依治疗用途分類的阿维莫泮市场

  • 阿片类药物引起的便秘
  • 术后肠阻塞的预防

第七章 Alvimopan 市场：依最终用户分类

  • 医院
  • 手术中心

第八章 南北美洲阿维莫泮市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章 Alvi Mopan亚太区市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲阿维莫泮市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Hikma Pharmaceuticals 在美国推出促进肠胃恢復的 Alvimopan 胶囊
  • 战略分析和建议

公司名单

  • Adolor Corporation
  • Adooq Bioscience LLC
  • Hikma Pharmaceuticals PLC
  • Manus Aktteva Biopharma LLP
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-151228454438

The Alvimopan Market was valued at USD 6.20 billion in 2023, expected to reach USD 6.51 billion in 2024, and is projected to grow at a CAGR of 5.23%, to USD 8.87 billion by 2030.

Alvimopan is a peripherally acting μ-opioid receptor antagonist primarily used to accelerate gastrointestinal recovery following bowel resection surgeries by mitigating opioid-induced gastrointestinal side effects. The necessity of Alvimopan stems from its critical role in enhancing postoperative recovery rates, reducing hospital stays, and decreasing healthcare costs, particularly in light of the increasing number of surgical procedures worldwide. It is predominantly applied in the healthcare setting by hospitals and surgical centers as a postoperative treatment agent. Alvimopan's end-use scope extends to the pharmaceutical sector with a focus on postoperative care and enhanced patient management protocols. The increasing emphasis on minimally invasive surgeries and rapid recovery protocols within healthcare systems is a significant growth factor for this market. Potential opportunities lie in expanding indications for its use beyond gastrointestinal recovery and exploring combination drug therapies that could widen its applicability. Engaging in strategic partnerships with healthcare institutions can enhance market penetration and reach. However, limitations such as regulatory challenges, high cost, and strict administration protocols pose significant hurdles. Resistance due to potential cardiovascular risks and associated stringent guidelines may also deter market expansion. Innovation opportunities exist in enhancing the bioavailability and efficacy of Alvimopan through advanced drug delivery systems, such as nanoparticle-based technologies or harnessing AI-driven drug design strategies to optimize its therapeutic efficacy. Research could focus on developing a broader spectrum μ-opioid receptor antagonist that retains the benefits of Alvimopan while reducing risks. The market for Alvimopan is niche and highly specialized, driven by strong clinical evidence supporting its effectiveness, but it requires navigating complex regulatory landscapes and demonstrating safety to sustain growth. Understanding market dynamics and integrating tailored marketing strategies can provide competitive advantages in this evolving domain.

KEY MARKET STATISTICS
Base Year [2023] USD 6.20 billion
Estimated Year [2024] USD 6.51 billion
Forecast Year [2030] USD 8.87 billion
CAGR (%) 5.23%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Alvimopan Market

The Alvimopan Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in surgical interventions including abdominal surgeries
    • Growing awareness and management strategies for opioid-induced complications
    • Improved healthcare facilities worldwide
  • Market Restraints
    • Strict regulations and long approval processes
  • Market Opportunities
    • R&D initiatives for exploring therapeutic applications of alvimopan
    • Increasing investments in public and private healthcare infrastructure
  • Market Challenges
    • Risk of associated side effects of alvimopan

Porter's Five Forces: A Strategic Tool for Navigating the Alvimopan Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Alvimopan Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Alvimopan Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Alvimopan Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Alvimopan Market

A detailed market share analysis in the Alvimopan Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Alvimopan Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Alvimopan Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Alvimopan Market

A strategic analysis of the Alvimopan Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Alvimopan Market, highlighting leading vendors and their innovative profiles. These include Adolor Corporation, Adooq Bioscience LLC, Hikma Pharmaceuticals PLC, Manus Aktteva Biopharma LLP, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Alvimopan Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Application, market is studied across Opioid-Induced Constipation and Postoperative Ileus Prevention.
  • Based on End-User, market is studied across Hospitals and Surgical Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in surgical interventions including abdominal surgeries
      • 5.1.1.2. Growing awareness and management strategies for opioid-induced complications
      • 5.1.1.3. Improved healthcare facilities worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulations and long approval processes
    • 5.1.3. Opportunities
      • 5.1.3.1. R&D initiatives for exploring therapeutic applications of alvimopan
      • 5.1.3.2. Increasing investments in public and private healthcare infrastructure
    • 5.1.4. Challenges
      • 5.1.4.1. Risk of associated side effects of alvimopan
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapeutic Application: Diverse scope of applications for easing opioid-Induced constipation
    • 5.2.2. End-User: Increasing preference for alvimopan in surgical centers for treating postoperative ileus
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Alvimopan Market, by Therapeutic Application

  • 6.1. Introduction
  • 6.2. Opioid-Induced Constipation
  • 6.3. Postoperative Ileus Prevention

7. Alvimopan Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Surgical Centers

8. Americas Alvimopan Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Alvimopan Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Alvimopan Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Hikma Pharmaceuticals Launches Alvimopan Capsules for Enhanced Gastrointestinal Recovery in the US
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adolor Corporation
  • 2. Adooq Bioscience LLC
  • 3. Hikma Pharmaceuticals PLC
  • 4. Manus Aktteva Biopharma LLP
  • 5. Merck & Co., Inc.
  • 6. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ALVIMOPAN MARKET RESEARCH PROCESS
  • FIGURE 2. ALVIMOPAN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALVIMOPAN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALVIMOPAN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ALVIMOPAN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ALVIMOPAN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALVIMOPAN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALVIMOPAN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALVIMOPAN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALVIMOPAN MARKET DYNAMICS
  • TABLE 7. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALVIMOPAN MARKET SIZE, BY OPIOID-INDUCED CONSTIPATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALVIMOPAN MARKET SIZE, BY POSTOPERATIVE ILEUS PREVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALVIMOPAN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALVIMOPAN MARKET SIZE, BY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ALVIMOPAN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. ALVIMOPAN MARKET, FPNV POSITIONING MATRIX, 2023